FiteBac Drug K21 QAS Preliminary Findings
FiteBac Dental, part of FiteBac Technology/Largent Health has FDA 510(k) Clearance with FiteBac Antimicrobial Cavity Cleanser (K190271).
FiteBac Antimicrobial Cavity Cleanser with active compound K21 QAS is the first FDA Cleared antimicrobial device for restorative dentistry.
Fitebac Dental lead molecules K18 QAMS and K21 QAS are cleared in dental devices and have applications in many medical devices.
FiteBac K21 QAS (Quaternary Ammonium Silane) has presented to FDA CDER (Center for Drug Evaluation and Research) as a NME (New Molecular Entity) with PIND 128706 Reference ID: 3948343 pursuing NDA for surgical hand rub.
This FDA application and US patent METHOD OF TREATING INFECTIONS USING SILOXANE DERIVATIVES US 15/517,060 as well as composition of matter patent TWO- AND THREECOMPONENT SILOXANES AND RELATED COMPOUNDS AND COMPOSITIONS awarded in USA, China, Hong Kong, Germany, France, and United Kingdom strengthens FiteBac’s legal rights to K21 drug.
Additional PCT application utilizing K21 in drug application has been filed.